董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel G. Teper | 男 | Director | 58 | 49.94万美元 | 未持股 | 2017-12-18 |
| Daniel Kazado | 男 | Chairman of the Board | 52 | 9.33万美元 | 未持股 | 2017-12-18 |
| Elliot Maza | 男 | President and Chief Executive Officer,Director | 62 | 9.33万美元 | 未持股 | 2017-12-18 |
| John Neczesny | 男 | Director | 54 | 9.35万美元 | 未持股 | 2017-12-18 |
| Cameron Durrant | 男 | Director | 57 | 12.25万美元 | 未持股 | 2017-12-18 |
| Jeffrey Paley | 男 | Director | 50 | 8.38万美元 | 未持股 | 2017-12-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elliot Maza | 男 | President and Chief Executive Officer,Director | 62 | 9.33万美元 | 未持股 | 2017-12-18 |
| Tony Fiorino | 男 | Chief Medical Officer and Chief Operating Officer | 50 | 未披露 | 未持股 | 2017-12-18 |
董事简历
中英对照 | 中文 | 英文- Daniel G. Teper
-
Daniel G. Teper， 药学博士。2013年8月25日合并后，他担任公司的主席和首席执行官。他成立了Immune Pharmaceuticals Ltd.；2010年1月至2013年8月25日担任主席和首席执行官。 2005至2009年，他担任全球管理咨询公司Bionest Partners的纽约总经理和北美主管， 为制药和上市生物技术公司提供关于公司战略、商业发展、合并与收购、新产品开发和商业化的意见。2000至2004年，在美国担任多个高级管理职位，包括互联网医疗保健公司Softwatch的销售与商业发展高级副总裁，协助风险融资3000万美元，公司雇员扩大至150人；1996至 1999年，担任Havas-Euro Rscg Healthcare Worldwide的全球总裁，扩大运营至全球范围，为制药公司提供多种疾病新药物的全球推广咨询服务。1984年，他在总部位于瑞士巴塞尔的Novartis开始职业生涯；1985至1990年在美国工作，负责市场营销，最终成为Cardiovascular Products的新产品开发主管；1990至 1992年，在法国担任普通管理职位，首先担任Laboratoires at GlaxoSmith Kline的高级副总裁和市场营销主管， 随后担任Laboratories at Delagrange的总裁和首席运营官，后者被Sanofi的继任公司Synthelabo收购。1993年，他成立了专业制药公司WINTEC Pharma并担任首席执行官。1995年，他将WINTEC Pharma的抗感染部门出售给英国的Norgine，将皮肤部门出售给比利时的Galephar。 1999年，他联合成立Novagali （NYSE Euronext： NOVA）， 该公司是专业的眼科制药公司，最近被日本的Santen收购。他在巴黎第六大学（Paris XI University）获得药学博士学位，在INSEAD获得工商管理硕士学位， 是萨蒙学者。
Daniel G. Teper, Pharm. D., M.B.A, served as the Chief Executive Officer of the Company from August 2013 until April 2017 when he resigned from such position to assume the position of Chief Executive Officer of Cytovia, Inc., a wholly-owned subsidiary of the Company. Dr. Teper was appointed to such Cief Executive Officer of the Company pursuant to the terms of the August 2013 merger transaction between the Company and Immune Pharmaceuticals Ltd. “Immune Ltd.”, now a wholly-owned subsidiary of the Company (the “Merger”). From August 25 2013 to December 15 2014 Dr. Teper served as Chairman of our Board of Directors. Dr. Teper founded Immune Pharmaceuticals Ltd. and served as its chairman and chief executive officer from January 2010 to August 2013. From 2005 to 2009 Dr. Teper served as New York-based Managing Partner and Head of North America at Bionest Partners, a global management consulting firm, where he advised pharmaceutical and public biotechnology companies with respect to corporate strategy, business development, mergers and acquisitions, new product development and commercialization. From 2000 to 2004 Dr. Teper held various senior management roles in the U.S., including senior vice president of sales and business development at Softwatch, an Internet healthcare company, where he assisted in raising $30 million in venture capital and expanding the company to over 150 employees. From 1996 to 1999 Dr. Teper served as global president of HAVAS-Euro Rscg Healthcare Worldwide, where he expanded operations internationally and advised pharmaceutical companies on global launches of major new drugs in multiple disease areas. Dr. Teper worked for Novartis from 1984 to 1990 serving at the headquarters in Basel, Switzerland from 1984 to 1985 and serving out of the U.S. from 1985 to 1990 during which time he held management responsibilities in sales and marketing and was appointed head of new product development for Cardiovascular Products. From 1990 to 1992 Dr. Teper held general management positions in France, including Senior Vice President and head of marketing and sales of Laboratories at GlaxoSmithKline and President and Chief Operating Officer of Laboratories at Delagrange (which was acquired by Synthelabo, a predecessor to Sanofi). In 1993 Dr. Teper founded and began serving as chief executive officer of WINTEC Pharma, a specialty pharmaceutical company. In 1995 Dr. Teper sold the anti-infectives segment of WINTEC Pharma to Norgine (UK) and the dermatology segment to Galephar (Belgium). In 1999 Dr. Teper co-founded Novagali (NYSE Euronext: NOVA), a pharmaceutical company specializing in ophthalmology and which was recently acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD, where he was a J. Salmon scholar. - Daniel G. Teper， 药学博士。2013年8月25日合并后，他担任公司的主席和首席执行官。他成立了Immune Pharmaceuticals Ltd.；2010年1月至2013年8月25日担任主席和首席执行官。 2005至2009年，他担任全球管理咨询公司Bionest Partners的纽约总经理和北美主管， 为制药和上市生物技术公司提供关于公司战略、商业发展、合并与收购、新产品开发和商业化的意见。2000至2004年，在美国担任多个高级管理职位，包括互联网医疗保健公司Softwatch的销售与商业发展高级副总裁，协助风险融资3000万美元，公司雇员扩大至150人；1996至 1999年，担任Havas-Euro Rscg Healthcare Worldwide的全球总裁，扩大运营至全球范围，为制药公司提供多种疾病新药物的全球推广咨询服务。1984年，他在总部位于瑞士巴塞尔的Novartis开始职业生涯；1985至1990年在美国工作，负责市场营销，最终成为Cardiovascular Products的新产品开发主管；1990至 1992年，在法国担任普通管理职位，首先担任Laboratoires at GlaxoSmith Kline的高级副总裁和市场营销主管， 随后担任Laboratories at Delagrange的总裁和首席运营官，后者被Sanofi的继任公司Synthelabo收购。1993年，他成立了专业制药公司WINTEC Pharma并担任首席执行官。1995年，他将WINTEC Pharma的抗感染部门出售给英国的Norgine，将皮肤部门出售给比利时的Galephar。 1999年，他联合成立Novagali （NYSE Euronext： NOVA）， 该公司是专业的眼科制药公司，最近被日本的Santen收购。他在巴黎第六大学（Paris XI University）获得药学博士学位，在INSEAD获得工商管理硕士学位， 是萨蒙学者。
- Daniel G. Teper, Pharm. D., M.B.A, served as the Chief Executive Officer of the Company from August 2013 until April 2017 when he resigned from such position to assume the position of Chief Executive Officer of Cytovia, Inc., a wholly-owned subsidiary of the Company. Dr. Teper was appointed to such Cief Executive Officer of the Company pursuant to the terms of the August 2013 merger transaction between the Company and Immune Pharmaceuticals Ltd. “Immune Ltd.”, now a wholly-owned subsidiary of the Company (the “Merger”). From August 25 2013 to December 15 2014 Dr. Teper served as Chairman of our Board of Directors. Dr. Teper founded Immune Pharmaceuticals Ltd. and served as its chairman and chief executive officer from January 2010 to August 2013. From 2005 to 2009 Dr. Teper served as New York-based Managing Partner and Head of North America at Bionest Partners, a global management consulting firm, where he advised pharmaceutical and public biotechnology companies with respect to corporate strategy, business development, mergers and acquisitions, new product development and commercialization. From 2000 to 2004 Dr. Teper held various senior management roles in the U.S., including senior vice president of sales and business development at Softwatch, an Internet healthcare company, where he assisted in raising $30 million in venture capital and expanding the company to over 150 employees. From 1996 to 1999 Dr. Teper served as global president of HAVAS-Euro Rscg Healthcare Worldwide, where he expanded operations internationally and advised pharmaceutical companies on global launches of major new drugs in multiple disease areas. Dr. Teper worked for Novartis from 1984 to 1990 serving at the headquarters in Basel, Switzerland from 1984 to 1985 and serving out of the U.S. from 1985 to 1990 during which time he held management responsibilities in sales and marketing and was appointed head of new product development for Cardiovascular Products. From 1990 to 1992 Dr. Teper held general management positions in France, including Senior Vice President and head of marketing and sales of Laboratories at GlaxoSmithKline and President and Chief Operating Officer of Laboratories at Delagrange (which was acquired by Synthelabo, a predecessor to Sanofi). In 1993 Dr. Teper founded and began serving as chief executive officer of WINTEC Pharma, a specialty pharmaceutical company. In 1995 Dr. Teper sold the anti-infectives segment of WINTEC Pharma to Norgine (UK) and the dermatology segment to Galephar (Belgium). In 1999 Dr. Teper co-founded Novagali (NYSE Euronext: NOVA), a pharmaceutical company specializing in ophthalmology and which was recently acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree from Paris XI University and an MBA from INSEAD, where he was a J. Salmon scholar.
- Daniel Kazado
-
Daniel Kazado， 2013年10月10日，他成为公司董事。2012年成立起，他担任Melini Capital的高级顾问， 该公司是家族私人和公共股本公司，投资国际上多个行业。Melini Capital是免疫制药业的一家新兴的重要的投资者。15年多时间里，他建立了自己的管理咨询公司，拥有25名专业人员，为多个行业董事会提供高级管理咨询服务，2002年将公司出售给年收入超过10亿美元的全球工程与管理咨询集团Altran Technologies。 他在法国Lyon University获得工商管理学士学位和管理硕士学位。
Daniel Kazado became a Director of the Company on October 19 2013 and became the Chairman of the Board of Directors on December 15 2014. Mr. Kazado has served as a senior advisor to Melini Capital, a family owned private and public equity firm investing internationally in several industries, since its incorporation in 2010. Melini Capital has been an early and significant investor in Immune Pharmaceuticals. From March 2011 to August 2013 Mr. Kazado served as a director. In 1992 Mr. Kazado founded DMA Altiam, a management consulting firm that advised boards of directors and senior management in multiple industries. DMA Altiam grew to include 25 professionals over the course of fifteen years, and in 2002 Mr. Kazado sold the company to Altran Technologies, a global engineering and management consulting group with revenues of over $1 billion. Mr. Kazado holds a bachelor’s degree in Business Administration and a master’s degree in Management from Lyon University in France. - Daniel Kazado， 2013年10月10日，他成为公司董事。2012年成立起，他担任Melini Capital的高级顾问， 该公司是家族私人和公共股本公司，投资国际上多个行业。Melini Capital是免疫制药业的一家新兴的重要的投资者。15年多时间里，他建立了自己的管理咨询公司，拥有25名专业人员，为多个行业董事会提供高级管理咨询服务，2002年将公司出售给年收入超过10亿美元的全球工程与管理咨询集团Altran Technologies。 他在法国Lyon University获得工商管理学士学位和管理硕士学位。
- Daniel Kazado became a Director of the Company on October 19 2013 and became the Chairman of the Board of Directors on December 15 2014. Mr. Kazado has served as a senior advisor to Melini Capital, a family owned private and public equity firm investing internationally in several industries, since its incorporation in 2010. Melini Capital has been an early and significant investor in Immune Pharmaceuticals. From March 2011 to August 2013 Mr. Kazado served as a director. In 1992 Mr. Kazado founded DMA Altiam, a management consulting firm that advised boards of directors and senior management in multiple industries. DMA Altiam grew to include 25 professionals over the course of fifteen years, and in 2002 Mr. Kazado sold the company to Altran Technologies, a global engineering and management consulting group with revenues of over $1 billion. Mr. Kazado holds a bachelor’s degree in Business Administration and a master’s degree in Management from Lyon University in France.
- Elliot Maza
-
Elliot Maza，2015年1月14日，成为本公司董事。此前，2014年11月至2015年1月，他是本公司的顾问；2006年5月至今，他在Intellect Neurosciences, Inc担任过一些管理职务，这是专注于Alzheimer病症疗法开发的生物技术公司；2006年5月至2007年3月，他担任其执行副总裁；2007年3月至2011年10月，担任总裁；2006年5月至今，他一直担任首席财务官。2007年6月26日，他被任命为该公司董事。2003年12月至2006年5月，他担任Emisphere Technologies, Inc的首席财务官，这是专注于口服给药的生物制药公司。1999年3月至2003年12月，他是Ernst and Young, LLP的合伙人。1989年5月至1999年3月，他在oldman Sachs, Inc、JP Morgan Securities, Inc的固定收益固定部门先后担任过助理、副总裁。1985-1989，他在纽约的Sullivan and Cromwell 从事税务、公司法的执业。
Elliot Maza, JD, CPA was appointed Chief Executive Officer of the Company in September 2017 after serving in this capacity on an interim basis since April 2017 and as a Director since January 2015. He was appointed President of the Company in November 2017. Mr. Maza served as a consultant to the Company from November 2014 to January 2015. Mr. Maza served as the Chairman of the Board of Directors, Chief Executive Officer and Chief Financial Officer of Intellect Neurosciences, Inc., a biotechnology company focused on the development of therapeutics for various CNS diseases from July 2014 until September 2017 and served as the Executive Vice President of Intellect Neurosciences, Inc. from May 2006 to March 2007 as President from March 2007 to October 2011 and as a consultant to Intellect Neurosciences, Inc. from November 2011 until July 2014. Mr. Maza was appointed to the board of directors of Intellect Neurosciences, Inc. on June 26 2007 Mr. Maza served as the Chief Executive Officer, Chief Financial Officer and member of the Board of Directors of Biozone Pharmaceuticals, Inc., a contract manufacturer of over-the-counter pharmaceuticals and skin care products, from August 2011 until January 2014. From December 2003 to May 2006 Mr. Maza served as Chief Financial Officer of Emisphere Technologies, Inc., a biopharmaceutical company specializing in oral drug delivery. From March 1999 to December 2003 Mr. Maza was a Partner, Transaction Advisory Services, at Ernst & Young, LLP. During the period from May 1989 to March 1999 Mr. Maza served as an Associate and subsequently Vice President in the Fixed Income divisions of Goldman Sachs, Inc. and JP Morgan Securities, Inc. Mr. Maza practiced law at Sullivan and Cromwell in New York from September 1985 to April 1989. Mr. Maza has served on numerous Boards of Directors for OTC and NASDAQ traded companies, including positions as Chairman of the Audit Committee. He is a registered attorney and a licensed C.P.A. inactive in the states of New York and New Jersey. He received a B.A. in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School. - Elliot Maza，2015年1月14日，成为本公司董事。此前，2014年11月至2015年1月，他是本公司的顾问；2006年5月至今，他在Intellect Neurosciences, Inc担任过一些管理职务，这是专注于Alzheimer病症疗法开发的生物技术公司；2006年5月至2007年3月，他担任其执行副总裁；2007年3月至2011年10月，担任总裁；2006年5月至今，他一直担任首席财务官。2007年6月26日，他被任命为该公司董事。2003年12月至2006年5月，他担任Emisphere Technologies, Inc的首席财务官，这是专注于口服给药的生物制药公司。1999年3月至2003年12月，他是Ernst and Young, LLP的合伙人。1989年5月至1999年3月，他在oldman Sachs, Inc、JP Morgan Securities, Inc的固定收益固定部门先后担任过助理、副总裁。1985-1989，他在纽约的Sullivan and Cromwell 从事税务、公司法的执业。
- Elliot Maza, JD, CPA was appointed Chief Executive Officer of the Company in September 2017 after serving in this capacity on an interim basis since April 2017 and as a Director since January 2015. He was appointed President of the Company in November 2017. Mr. Maza served as a consultant to the Company from November 2014 to January 2015. Mr. Maza served as the Chairman of the Board of Directors, Chief Executive Officer and Chief Financial Officer of Intellect Neurosciences, Inc., a biotechnology company focused on the development of therapeutics for various CNS diseases from July 2014 until September 2017 and served as the Executive Vice President of Intellect Neurosciences, Inc. from May 2006 to March 2007 as President from March 2007 to October 2011 and as a consultant to Intellect Neurosciences, Inc. from November 2011 until July 2014. Mr. Maza was appointed to the board of directors of Intellect Neurosciences, Inc. on June 26 2007 Mr. Maza served as the Chief Executive Officer, Chief Financial Officer and member of the Board of Directors of Biozone Pharmaceuticals, Inc., a contract manufacturer of over-the-counter pharmaceuticals and skin care products, from August 2011 until January 2014. From December 2003 to May 2006 Mr. Maza served as Chief Financial Officer of Emisphere Technologies, Inc., a biopharmaceutical company specializing in oral drug delivery. From March 1999 to December 2003 Mr. Maza was a Partner, Transaction Advisory Services, at Ernst & Young, LLP. During the period from May 1989 to March 1999 Mr. Maza served as an Associate and subsequently Vice President in the Fixed Income divisions of Goldman Sachs, Inc. and JP Morgan Securities, Inc. Mr. Maza practiced law at Sullivan and Cromwell in New York from September 1985 to April 1989. Mr. Maza has served on numerous Boards of Directors for OTC and NASDAQ traded companies, including positions as Chairman of the Audit Committee. He is a registered attorney and a licensed C.P.A. inactive in the states of New York and New Jersey. He received a B.A. in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School.
- John Neczesny
-
John Neczesny2016年2月2日成为本公司的董事。自2012年起，Neczesny先生一直在Oberon Securities, LLC（一家精品投资银行）担任董事总经理，在那里他建议并主要执行医疗保健公司的并购和融资交易。此前，2009年至2011年他是Par Pharmaceutical Companies企业发展的副总裁。1998年至2008年，Neczesny先生曾是Bear Stearns & Co. Inc. 的医疗集团的一名投资银行家，在那里他升到了总经理，并参与了许多制药、生物技术和医疗技术公司的并购和资本市场交易。 Neczesny先生拥有New York University Stern School of Business 的金融工商管理硕士学位和University of Delaware的化学理学士学位。
John Neczesny became a Director of the Company on February 2 2016. Mr. Neczesny is a Managing Partner at Blue Ox Healthcare Partners, LLC, a private investment firm providing capital to growth-stage healthcare companies. He was previously a Managing Director at Oberon Securities, LLC as an investment banker to healthcare companies and Vice President, Corporate Development at Par Pharmaceutical Companies. From 1998 to 2008 Mr. Neczesny was an investment banker at Bear Stearns & Co. Inc. in the Healthcare group, where he rose to Managing Director and was involved in numerous M&A and capital markets transactions for pharmaceutical, biotechnology and medical technology companies. Prior to his corporate finance career, he spent 9 years in business development and project management roles in contract laboratory and data management businesses. Mr. Neczesny earned an MBA in Finance from New York University Stern School of Business and a Bachelor of Science degree in Chemistry from the University of Delaware. - John Neczesny2016年2月2日成为本公司的董事。自2012年起，Neczesny先生一直在Oberon Securities, LLC（一家精品投资银行）担任董事总经理，在那里他建议并主要执行医疗保健公司的并购和融资交易。此前，2009年至2011年他是Par Pharmaceutical Companies企业发展的副总裁。1998年至2008年，Neczesny先生曾是Bear Stearns & Co. Inc. 的医疗集团的一名投资银行家，在那里他升到了总经理，并参与了许多制药、生物技术和医疗技术公司的并购和资本市场交易。 Neczesny先生拥有New York University Stern School of Business 的金融工商管理硕士学位和University of Delaware的化学理学士学位。
- John Neczesny became a Director of the Company on February 2 2016. Mr. Neczesny is a Managing Partner at Blue Ox Healthcare Partners, LLC, a private investment firm providing capital to growth-stage healthcare companies. He was previously a Managing Director at Oberon Securities, LLC as an investment banker to healthcare companies and Vice President, Corporate Development at Par Pharmaceutical Companies. From 1998 to 2008 Mr. Neczesny was an investment banker at Bear Stearns & Co. Inc. in the Healthcare group, where he rose to Managing Director and was involved in numerous M&A and capital markets transactions for pharmaceutical, biotechnology and medical technology companies. Prior to his corporate finance career, he spent 9 years in business development and project management roles in contract laboratory and data management businesses. Mr. Neczesny earned an MBA in Finance from New York University Stern School of Business and a Bachelor of Science degree in Chemistry from the University of Delaware.
- Cameron Durrant
-
Cameron Durrant，医学博士于2014年7月加入我们的董事会。Durrant博士是Humanigen，Inc.前KaloBiosPharmaceuticals，Inc.（OTC:HGEN）的首席执行官兼董事会主席，自2016年3月1日起生效。Durrant博士于2012年9月至2014年4月担任Hi-TechPharmacalCo.，Inc.（纳斯达克市场代码:HITK）子公司ECR Pharmaceuticals Co.，Inc.（“；ECR”；）的总裁兼首席执行官。从2010年1月至2012年9月，Durrant博士担任几家生物制药公司的顾问，担任PediatRx，Inc.（随后剥离）的创始人，首席执行官兼首席财务官，并在几家生物技术和医疗设备公司董事会任职。以及担任首席执行官和首席财务官，他曾担任主席、财务主管和首席会计官，并召集、参加或主持审计、提名、治理、薪酬和特殊董事委员会。他曾一直担任Blue-Chip Big Pharma公司的高管，包括Johnson and Johnson公司、Pharmacia Corporation（直到被Pfizer公司收购）、GSK公司和Merck公司。他是Bexion Pharmaceuticals公司（一家拥有I期、新型脂质/蛋白质纳米技术肿瘤治疗的私人公司）的创始董事，以及Alcyone Life Sciences公司（一家私人医疗设备公司）的董事会成员。他曾担任PediatRx公司（上市公司）的创始投资者、主席、首席执行官兼首席财务官、Anavex公司（上市公司）的执行主席兼首席执行官、Pressure Point公司（医疗器械公司）的前任主席、Pediamed Pharmaceuticals（被Connetics Corporation收购）的前首席执行官和Topaz Pharmaceuticals（被Sanofi-Aventis收购）的前董事会成员。他是2005年安永（Ernst and Young）俄亥俄州和肯塔基州年度企业家奖（Entrepreneur of the Year）的获得者，也是全国决赛选手，被PharmaVoice2005年、2006年、2007年和2010年评选为制药行业100位最鼓舞人心的人物之一，并于2008年被制药高管评为“改变一代——制药行业值得关注的年轻领袖”之一。卡梅伦在英国加的夫威尔士国家医学院获得医学博士学位，在英国伦敦皇家妇产科医学院获得DRCOG学位，在英国伦敦皇家全科医师学院获得MRCGP学位，在墨尔本学院获得DIPCH学位，Australia和他的英国牛津郡Henley Management College工商管理硕士学位。
Cameron Durrant, M. D. joined our board of directors in July 2014. Dr. Durrant is CEO and Chairman of the Board of Humanigen, Inc. formerly KaloBios Pharmaceuticals, Inc. (OTC: HGEN), effective as of March 1 2016. Dr. Durrant served as President and Chief Executive Officer of ECR Pharmaceuticals Co., Inc. (“ECR”) a subsidiary of Hi-tech Pharmacal Co., Inc. (NASDAQ: HITK), from September 2012 to April 2014. From January 2010 to September 2012 Dr. Durrant served as a consultant to several biopharma companies, as the Founder, CEO and CFO of PediatRx, Inc. (subsequently divested) and on several biotech and medical device company boards. As well as holding CEO and CFO roles, he has acted as Chairman, Treasurer and Chief Accounting Officer and convened, sat on or chaired audit, nominating, governance, compensation and special board committees. He has been an executive at blue-chip big pharma, including Johnson and Johnson, Pharmacia Corporation (until its acquisition by Pfizer), GSK and Merck. He is a founding director of Bexion Pharmaceuticals, a private company with a Phase I, novel lipid/protein nanotech oncology therapeutic and a board member of Alcyone Life Sciences, a private medical device company. He has served as a founding investor, Chairman, CEO and CFO of PediatRx (a public company), Executive Chairman and CEO of Anavex (a public company), former Chairman of Pressure Point (a medical device company), former CEO of PediaMed Pharmaceuticals (acquired by Connetics Corporation) and former board member of Topaz Pharmaceuticals (acquired by sanofi-aventis). He was the 2005 winner of the Ernst and Young Ohio and Kentucky ‘Entrepreneur of the Year’ winner and a national finalist, named in the PharmaVoice 2005 2006 2007 and 2010 list of one of the ‘100 most inspiring people in the pharmaceutical industry’ and by Pharmaceutical Executive in 2008 as part of the ‘Change generation - young leaders to watch in pharma’. Cameron earned his MD from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia and his MBA from Henley Management College, Oxfordshire, UK. - Cameron Durrant，医学博士于2014年7月加入我们的董事会。Durrant博士是Humanigen，Inc.前KaloBiosPharmaceuticals，Inc.（OTC:HGEN）的首席执行官兼董事会主席，自2016年3月1日起生效。Durrant博士于2012年9月至2014年4月担任Hi-TechPharmacalCo.，Inc.（纳斯达克市场代码:HITK）子公司ECR Pharmaceuticals Co.，Inc.（“；ECR”；）的总裁兼首席执行官。从2010年1月至2012年9月，Durrant博士担任几家生物制药公司的顾问，担任PediatRx，Inc.（随后剥离）的创始人，首席执行官兼首席财务官，并在几家生物技术和医疗设备公司董事会任职。以及担任首席执行官和首席财务官，他曾担任主席、财务主管和首席会计官，并召集、参加或主持审计、提名、治理、薪酬和特殊董事委员会。他曾一直担任Blue-Chip Big Pharma公司的高管，包括Johnson and Johnson公司、Pharmacia Corporation（直到被Pfizer公司收购）、GSK公司和Merck公司。他是Bexion Pharmaceuticals公司（一家拥有I期、新型脂质/蛋白质纳米技术肿瘤治疗的私人公司）的创始董事，以及Alcyone Life Sciences公司（一家私人医疗设备公司）的董事会成员。他曾担任PediatRx公司（上市公司）的创始投资者、主席、首席执行官兼首席财务官、Anavex公司（上市公司）的执行主席兼首席执行官、Pressure Point公司（医疗器械公司）的前任主席、Pediamed Pharmaceuticals（被Connetics Corporation收购）的前首席执行官和Topaz Pharmaceuticals（被Sanofi-Aventis收购）的前董事会成员。他是2005年安永（Ernst and Young）俄亥俄州和肯塔基州年度企业家奖（Entrepreneur of the Year）的获得者，也是全国决赛选手，被PharmaVoice2005年、2006年、2007年和2010年评选为制药行业100位最鼓舞人心的人物之一，并于2008年被制药高管评为“改变一代——制药行业值得关注的年轻领袖”之一。卡梅伦在英国加的夫威尔士国家医学院获得医学博士学位，在英国伦敦皇家妇产科医学院获得DRCOG学位，在英国伦敦皇家全科医师学院获得MRCGP学位，在墨尔本学院获得DIPCH学位，Australia和他的英国牛津郡Henley Management College工商管理硕士学位。
- Cameron Durrant, M. D. joined our board of directors in July 2014. Dr. Durrant is CEO and Chairman of the Board of Humanigen, Inc. formerly KaloBios Pharmaceuticals, Inc. (OTC: HGEN), effective as of March 1 2016. Dr. Durrant served as President and Chief Executive Officer of ECR Pharmaceuticals Co., Inc. (“ECR”) a subsidiary of Hi-tech Pharmacal Co., Inc. (NASDAQ: HITK), from September 2012 to April 2014. From January 2010 to September 2012 Dr. Durrant served as a consultant to several biopharma companies, as the Founder, CEO and CFO of PediatRx, Inc. (subsequently divested) and on several biotech and medical device company boards. As well as holding CEO and CFO roles, he has acted as Chairman, Treasurer and Chief Accounting Officer and convened, sat on or chaired audit, nominating, governance, compensation and special board committees. He has been an executive at blue-chip big pharma, including Johnson and Johnson, Pharmacia Corporation (until its acquisition by Pfizer), GSK and Merck. He is a founding director of Bexion Pharmaceuticals, a private company with a Phase I, novel lipid/protein nanotech oncology therapeutic and a board member of Alcyone Life Sciences, a private medical device company. He has served as a founding investor, Chairman, CEO and CFO of PediatRx (a public company), Executive Chairman and CEO of Anavex (a public company), former Chairman of Pressure Point (a medical device company), former CEO of PediaMed Pharmaceuticals (acquired by Connetics Corporation) and former board member of Topaz Pharmaceuticals (acquired by sanofi-aventis). He was the 2005 winner of the Ernst and Young Ohio and Kentucky ‘Entrepreneur of the Year’ winner and a national finalist, named in the PharmaVoice 2005 2006 2007 and 2010 list of one of the ‘100 most inspiring people in the pharmaceutical industry’ and by Pharmaceutical Executive in 2008 as part of the ‘Change generation - young leaders to watch in pharma’. Cameron earned his MD from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia and his MBA from Henley Management College, Oxfordshire, UK.
- Jeffrey Paley
-
Jeffrey Paley，自2013年11月15日以来，是该公司的一位董事。自2003年以来，是一家提供综合成人初级保健服务和急性护理的临床医疗公司- Access Medical Associates, PC的创始人；以及是一家为金融机构关于医疗投资决策提供咨询服务的公司- Crimson Biomedical Consulting的创始人和首席执行官。他目前在一家私营的风险支持生物技术公司- Kellbenx担任董事。拥有从Yeshiva大学获得的数学学士学位和犹太法学博士学位；以及拥有从哈佛医学院（Harvard Medical School）获得的医学博士学位。他曾在马萨诸塞总医院哈佛医学院（Massachusetts General Hospital Harvard Medical School）完成他的内科驻校研究。
Jeffrey Paley, M.D. became a Director of the Company on February 23 2016. Dr. Paley has been an active clinician and consultant for over 30 analysts and portfolio managers in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology arenas, reviewing the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices. Dr. Paley has also consulted for several biotechnology and specialty pharmaceutical companies, most notably in the areas of clinical development and business development and he has engineered transactions worth over $600 million. Dr. Paley founded Access Medical Associates in 2003 after spending five years on the full-time academic faculty of Weill Cornell Medical College, where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. At Weill Cornell, Dr. Paley was a Principal or Co-Principal Investigator on several studies of diabetes, hypertension, and cholesterol disorders. He has served as a Director of Kellbenx and Retrophin and currently serves as a Director of Kalytera, Avenue Therapeutics and Remote Radiology Inc. Dr. Paley trained at Harvard Medical School and completed a residency in Internal Medicine at Massachusetts General Hospital. - Jeffrey Paley，自2013年11月15日以来，是该公司的一位董事。自2003年以来，是一家提供综合成人初级保健服务和急性护理的临床医疗公司- Access Medical Associates, PC的创始人；以及是一家为金融机构关于医疗投资决策提供咨询服务的公司- Crimson Biomedical Consulting的创始人和首席执行官。他目前在一家私营的风险支持生物技术公司- Kellbenx担任董事。拥有从Yeshiva大学获得的数学学士学位和犹太法学博士学位；以及拥有从哈佛医学院（Harvard Medical School）获得的医学博士学位。他曾在马萨诸塞总医院哈佛医学院（Massachusetts General Hospital Harvard Medical School）完成他的内科驻校研究。
- Jeffrey Paley, M.D. became a Director of the Company on February 23 2016. Dr. Paley has been an active clinician and consultant for over 30 analysts and portfolio managers in the biotechnology, pharmaceutical, specialty pharmaceutical and medical technology arenas, reviewing the clinical, preclinical and regulatory pedigrees of numerous therapeutics and devices. Dr. Paley has also consulted for several biotechnology and specialty pharmaceutical companies, most notably in the areas of clinical development and business development and he has engineered transactions worth over $600 million. Dr. Paley founded Access Medical Associates in 2003 after spending five years on the full-time academic faculty of Weill Cornell Medical College, where he served as a Director of Clinical Research at the Cornell Internal Medicine Associates. At Weill Cornell, Dr. Paley was a Principal or Co-Principal Investigator on several studies of diabetes, hypertension, and cholesterol disorders. He has served as a Director of Kellbenx and Retrophin and currently serves as a Director of Kalytera, Avenue Therapeutics and Remote Radiology Inc. Dr. Paley trained at Harvard Medical School and completed a residency in Internal Medicine at Massachusetts General Hospital.
高管简历
中英对照 | 中文 | 英文- Elliot Maza
Elliot Maza，2015年1月14日，成为本公司董事。此前，2014年11月至2015年1月，他是本公司的顾问；2006年5月至今，他在Intellect Neurosciences, Inc担任过一些管理职务，这是专注于Alzheimer病症疗法开发的生物技术公司；2006年5月至2007年3月，他担任其执行副总裁；2007年3月至2011年10月，担任总裁；2006年5月至今，他一直担任首席财务官。2007年6月26日，他被任命为该公司董事。2003年12月至2006年5月，他担任Emisphere Technologies, Inc的首席财务官，这是专注于口服给药的生物制药公司。1999年3月至2003年12月，他是Ernst and Young, LLP的合伙人。1989年5月至1999年3月，他在oldman Sachs, Inc、JP Morgan Securities, Inc的固定收益固定部门先后担任过助理、副总裁。1985-1989，他在纽约的Sullivan and Cromwell 从事税务、公司法的执业。
Elliot Maza, JD, CPA was appointed Chief Executive Officer of the Company in September 2017 after serving in this capacity on an interim basis since April 2017 and as a Director since January 2015. He was appointed President of the Company in November 2017. Mr. Maza served as a consultant to the Company from November 2014 to January 2015. Mr. Maza served as the Chairman of the Board of Directors, Chief Executive Officer and Chief Financial Officer of Intellect Neurosciences, Inc., a biotechnology company focused on the development of therapeutics for various CNS diseases from July 2014 until September 2017 and served as the Executive Vice President of Intellect Neurosciences, Inc. from May 2006 to March 2007 as President from March 2007 to October 2011 and as a consultant to Intellect Neurosciences, Inc. from November 2011 until July 2014. Mr. Maza was appointed to the board of directors of Intellect Neurosciences, Inc. on June 26 2007 Mr. Maza served as the Chief Executive Officer, Chief Financial Officer and member of the Board of Directors of Biozone Pharmaceuticals, Inc., a contract manufacturer of over-the-counter pharmaceuticals and skin care products, from August 2011 until January 2014. From December 2003 to May 2006 Mr. Maza served as Chief Financial Officer of Emisphere Technologies, Inc., a biopharmaceutical company specializing in oral drug delivery. From March 1999 to December 2003 Mr. Maza was a Partner, Transaction Advisory Services, at Ernst & Young, LLP. During the period from May 1989 to March 1999 Mr. Maza served as an Associate and subsequently Vice President in the Fixed Income divisions of Goldman Sachs, Inc. and JP Morgan Securities, Inc. Mr. Maza practiced law at Sullivan and Cromwell in New York from September 1985 to April 1989. Mr. Maza has served on numerous Boards of Directors for OTC and NASDAQ traded companies, including positions as Chairman of the Audit Committee. He is a registered attorney and a licensed C.P.A. inactive in the states of New York and New Jersey. He received a B.A. in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School.- Elliot Maza，2015年1月14日，成为本公司董事。此前，2014年11月至2015年1月，他是本公司的顾问；2006年5月至今，他在Intellect Neurosciences, Inc担任过一些管理职务，这是专注于Alzheimer病症疗法开发的生物技术公司；2006年5月至2007年3月，他担任其执行副总裁；2007年3月至2011年10月，担任总裁；2006年5月至今，他一直担任首席财务官。2007年6月26日，他被任命为该公司董事。2003年12月至2006年5月，他担任Emisphere Technologies, Inc的首席财务官，这是专注于口服给药的生物制药公司。1999年3月至2003年12月，他是Ernst and Young, LLP的合伙人。1989年5月至1999年3月，他在oldman Sachs, Inc、JP Morgan Securities, Inc的固定收益固定部门先后担任过助理、副总裁。1985-1989，他在纽约的Sullivan and Cromwell 从事税务、公司法的执业。
- Elliot Maza, JD, CPA was appointed Chief Executive Officer of the Company in September 2017 after serving in this capacity on an interim basis since April 2017 and as a Director since January 2015. He was appointed President of the Company in November 2017. Mr. Maza served as a consultant to the Company from November 2014 to January 2015. Mr. Maza served as the Chairman of the Board of Directors, Chief Executive Officer and Chief Financial Officer of Intellect Neurosciences, Inc., a biotechnology company focused on the development of therapeutics for various CNS diseases from July 2014 until September 2017 and served as the Executive Vice President of Intellect Neurosciences, Inc. from May 2006 to March 2007 as President from March 2007 to October 2011 and as a consultant to Intellect Neurosciences, Inc. from November 2011 until July 2014. Mr. Maza was appointed to the board of directors of Intellect Neurosciences, Inc. on June 26 2007 Mr. Maza served as the Chief Executive Officer, Chief Financial Officer and member of the Board of Directors of Biozone Pharmaceuticals, Inc., a contract manufacturer of over-the-counter pharmaceuticals and skin care products, from August 2011 until January 2014. From December 2003 to May 2006 Mr. Maza served as Chief Financial Officer of Emisphere Technologies, Inc., a biopharmaceutical company specializing in oral drug delivery. From March 1999 to December 2003 Mr. Maza was a Partner, Transaction Advisory Services, at Ernst & Young, LLP. During the period from May 1989 to March 1999 Mr. Maza served as an Associate and subsequently Vice President in the Fixed Income divisions of Goldman Sachs, Inc. and JP Morgan Securities, Inc. Mr. Maza practiced law at Sullivan and Cromwell in New York from September 1985 to April 1989. Mr. Maza has served on numerous Boards of Directors for OTC and NASDAQ traded companies, including positions as Chairman of the Audit Committee. He is a registered attorney and a licensed C.P.A. inactive in the states of New York and New Jersey. He received a B.A. in Accounting from Touro College in New York and a J.D. from the University of Pennsylvania Law School.
- Tony Fiorino
Tony Fiorino，医学博士，博士，于2017年8月被任命为公司首席医疗官和首席运营官。Fiorino博士于2015年至2017年担任Triumvira Immunologics（一家免疫肿瘤公司，开发新型工程T细胞平台）的总裁兼首席执行官。Fiorino博士曾于2014年至2015年担任Brainstorm Cell Therapeutics（纳斯达克股票代码:BCLI）的首席执行官，该公司是用于神经退行性疾病的成人干细胞技术的领先开发商。任职期间，Brainstorm进行了肌萎缩性侧索硬化症神经营养因子分泌间充质干细胞的2期试验，筹集了2500万美元的股本，并在纳斯达克上市。他曾担任Enzymerx公司的创始人、总裁兼首席执行官（2008年至2010年），在那里他曾领导收购后期临床前生物制剂和化合物的开发（通过2期临床试验），随后出售给3SBIO公司，并从2008年到2014年担任生物技术和制药公司以及投资基金的独立顾问。创立Enzymerx之前，Fiorino博士在JP Morgan、Citigroup和Pequot Capital等公司担任生物技术与制药分析师和投资组合经理。Fiorino博士在阿尔伯特爱因斯坦医学院（Albert Einstein College of Medicine）获得医学博士学位和博士学位，在那里他研究肝祖细胞的分化，并在麻省理工学院（Massachusetts Institute of Technology）获得学士学位。
Tony Fiorino, M.D., Ph.D. was appointed Chief Medical Officer and Chief Operating Officer of the Company in August 2017. Dr. Fiorino served as President and Chief Executive Officer of Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, 2015-2017. Dr. Fiorino was the Chief Executive Officer of BrainStorm Cell Therapeutics NASDAQ:BCLI a leading developer of adult stem cell technologies for neurodegenerative diseases, 2014-2015. During his tenure, BrainStorm conducted a phase 2 trial of neurotrophic factor-secreting mesenchymal stem cells in amyotrophic lateral sclerosis, raised $25 million in equity capital, and uplisted to the Nasdaq. Dr. Fiorino was the Founder, President and CEO of EnzymeRx from 2008-2010 where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through phase 2 clinical trials and its subsequent sale to 3SBio, and worked as an independent consultant to biotechnology and pharmaceutical companies and investment funds from 2008-2014. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Dr. Fiorino earned an MD and a PhD from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.- Tony Fiorino，医学博士，博士，于2017年8月被任命为公司首席医疗官和首席运营官。Fiorino博士于2015年至2017年担任Triumvira Immunologics（一家免疫肿瘤公司，开发新型工程T细胞平台）的总裁兼首席执行官。Fiorino博士曾于2014年至2015年担任Brainstorm Cell Therapeutics（纳斯达克股票代码:BCLI）的首席执行官，该公司是用于神经退行性疾病的成人干细胞技术的领先开发商。任职期间，Brainstorm进行了肌萎缩性侧索硬化症神经营养因子分泌间充质干细胞的2期试验，筹集了2500万美元的股本，并在纳斯达克上市。他曾担任Enzymerx公司的创始人、总裁兼首席执行官（2008年至2010年），在那里他曾领导收购后期临床前生物制剂和化合物的开发（通过2期临床试验），随后出售给3SBIO公司，并从2008年到2014年担任生物技术和制药公司以及投资基金的独立顾问。创立Enzymerx之前，Fiorino博士在JP Morgan、Citigroup和Pequot Capital等公司担任生物技术与制药分析师和投资组合经理。Fiorino博士在阿尔伯特爱因斯坦医学院（Albert Einstein College of Medicine）获得医学博士学位和博士学位，在那里他研究肝祖细胞的分化，并在麻省理工学院（Massachusetts Institute of Technology）获得学士学位。
- Tony Fiorino, M.D., Ph.D. was appointed Chief Medical Officer and Chief Operating Officer of the Company in August 2017. Dr. Fiorino served as President and Chief Executive Officer of Triumvira Immunologics, an immuno-oncology company developing a novel engineered T cell platform, 2015-2017. Dr. Fiorino was the Chief Executive Officer of BrainStorm Cell Therapeutics NASDAQ:BCLI a leading developer of adult stem cell technologies for neurodegenerative diseases, 2014-2015. During his tenure, BrainStorm conducted a phase 2 trial of neurotrophic factor-secreting mesenchymal stem cells in amyotrophic lateral sclerosis, raised $25 million in equity capital, and uplisted to the Nasdaq. Dr. Fiorino was the Founder, President and CEO of EnzymeRx from 2008-2010 where he led the acquisition of a late-stage pre-clinical biologic and the development of the compound through phase 2 clinical trials and its subsequent sale to 3SBio, and worked as an independent consultant to biotechnology and pharmaceutical companies and investment funds from 2008-2014. Before founding EnzymeRx, Dr. Fiorino worked as a biotechnology and pharmaceuticals analyst and portfolio manager at firms including JP Morgan, Citigroup, and Pequot Capital. Dr. Fiorino earned an MD and a PhD from the Albert Einstein College of Medicine, where he studied the differentiation of liver progenitor cells, and a BS from the Massachusetts Institute of Technology.